KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Bristol Myers Squibb (BMY) Research & Development (2016 - 2025)

Bristol Myers Squibb (BMY) has disclosed Research & Development for 17 consecutive years, with $2.6 billion as the latest value for Q4 2025.

  • On a quarterly basis, Research & Development fell 18.96% to $2.6 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $10.0 billion, a 10.83% decrease, with the full-year FY2025 number at $10.0 billion, down 10.83% from a year prior.
  • Research & Development was $2.6 billion for Q4 2025 at Bristol Myers Squibb, up from $2.5 billion in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $3.3 billion in Q3 2021 to a low of $2.2 billion in Q1 2021.
  • A 5-year average of $2.5 billion and a median of $2.5 billion in 2021 define the central range for Research & Development.
  • Peak YoY movement for Research & Development: surged 30.09% in 2021, then decreased 25.62% in 2022.
  • Bristol Myers Squibb's Research & Development stood at $2.5 billion in 2021, then decreased by 0.32% to $2.5 billion in 2022, then decreased by 1.27% to $2.5 billion in 2023, then rose by 28.77% to $3.2 billion in 2024, then decreased by 18.96% to $2.6 billion in 2025.
  • Per Business Quant, the three most recent readings for BMY's Research & Development are $2.6 billion (Q4 2025), $2.5 billion (Q3 2025), and $2.6 billion (Q2 2025).